Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …

Background H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

Aurora kinase A (AURKA) has emerged as a drug target for glioblastoma (GBM). However,
resistance to therapy remains a critical issue. By integration of transcriptome, chromatin …

The discovery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) along with
its potent and selective antitumor effects initiated a decades-long search for therapeutic …

Background ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic
protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent …

Simple Summary Mitochondria, often called “the powerhouse of the cell”, generate most of
the energy required for all cellular processes. Mitochondria also provide a platform for …

Bromodomain and extraterminal domain proteins, especially bromodomain‑containing
protein 4 (Brd4), have recently emerged as therapeutic targets for several cancers, although …

Abstract The POU Class Homeobox 2 (POU2F2) is a member of POU transcription factors
family, which involves in cell immune response by regulating B cell proliferation and …

Background ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the
blood–brain barrier. ONC201 efficacy has been shown in glioblastoma animal models and …